Oncology Institute Inc
Change company Symbol lookup
Select an option...
TOI Oncology Institute Inc
AHI Advanced Health Intelligence Ltd
SNTG Sentage Holdings Inc
MDGS Medigus Ltd
WLDS Wearable Devices Ltd
UP Wheels Up Experience Inc
BRTX BioRestorative Therapies Inc
FRZA Forza X1 Inc
ILMN Illumina Inc
NR Newpark Resources Inc

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Health Care Providers & Services | Small Cap Value
Company profile

The Oncology Institute, Inc. is a value-based oncology company. The Company manages community-based oncology practices that serve patients at approximately 76 clinic locations across 15 markets and five states throughout the United States. The Company's segment includes dispensary, patient care, and clinical trials & other. Its managed clinics provide a range of medical oncology services, including physician services, in-house infusion and dispensary, clinical trial services, radiation, programs like outpatient blood product transfusions, along with 24/7 patient support. The Company, through TOI Clinical Research, LLC (TCR), provides and manages clinical trial services and research for the benefit of cancer patients. The Company also provides management services to 14 clinic locations owned by independent oncology practices. The Company's managed clinics primarily serve adult and senior cancer patients in markets that have Medicare Advantage (MA) plans.

Closing Price
Day's Change
-0.0348 (-5.31%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

Fresh Del Monte posts surprise Q4 profit as sales top estimates

6:33 am ET February 22, 2023 (MarketWatch)

Fresh Del Monte Produce Inc. (FDP) said Wednesday it had net income of $18.3 million, or 38 cents a share, for the fourth quarter, after a loss of $11.2 million, or 24 cents a share, in the year-earlier period. Adjusted per-share earnings came to 45 cents, well ahead of the FactSet consensus for a loss of 4 cents. Sales edged down to $1.040 billion from $1.018 billion a year ago, but also beat the $1.034 billion FactSet consensus. Chief Executive Mohammad Abu-Ghazaleh said the company closed out the year in a stronger position than 2021. Sales growth was driven by "inflation-justified" per unit price increases, which were partially offset by lower sales volume, mostly in the banana and fresh and value-added products segments, and the strong dollar. Banana sales rose 9% to $32.9 million, while fresh and value-added product sales fell 4% to $21.8 million, due to lower sales of avocados, and non-tropical fruit, which was hurt by lower prices and lower volumes. The stock has gained 1.7% in the last 12 months, while the S&P 500 has fallen 7%.

-Ciara Linnane


(END) Dow Jones Newswires

February 22, 2023 06:33 ET (11:33 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.